Dampening Ab responses using proteasome inhibitors following in vivo B cell activation

Paolo Cascio, Laura Oliva, Fulvia Cerruti, Elisabetta Mariani, Elena Pasqualetto, Simone Cenci, Roberto Sitia

Research output: Contribution to journalArticle

Abstract

Upon encounter with Ag, B lymphocytes undergo terminal differentiation into plasma cells, highly specialized Ab secretors that mediate humoral immune responses. Profound changes adapt cellular morphology and proteome to the new secretory functions. Although a massive secretory activity is expected to require an efficient ubiquitin-proteasome degradation system, recent in vitro studies have surprisingly revealed that the proteasome function sharply decreases during plasma cell development, thereby limiting the proteolytic capacity. We challenged this paradigm in mouse models of B cell activation, and observed that following polyclonal activation, proteasome activity decreases more than previously reported in vitro. This decrease is linked to enhanced apoptosis after treatment with the potent anti-myeloma proteasome inhibitor PS-341. Accordingly, in vivo treatment with PS-341 decreases Ab titres in T-dependent and -independent mouse immunization models. This study provides the rationale for limiting the activity of Ab-secreting cells in vivo by impacting proteasome function.

Original languageEnglish
Pages (from-to)658-667
Number of pages10
JournalEuropean Journal of Immunology
Volume38
Issue number3
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Proteasome Inhibitors
Proteasome Endopeptidase Complex
B-Lymphocytes
Plasma Cells
Proteome
Humoral Immunity
Ubiquitin
Immunization
Apoptosis
Therapeutics
In Vitro Techniques
Bortezomib

Keywords

  • Antibodies
  • Apoptosis
  • B cells
  • Cell differentiation
  • Proteasomes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. / Cascio, Paolo; Oliva, Laura; Cerruti, Fulvia; Mariani, Elisabetta; Pasqualetto, Elena; Cenci, Simone; Sitia, Roberto.

In: European Journal of Immunology, Vol. 38, No. 3, 03.2008, p. 658-667.

Research output: Contribution to journalArticle

Cascio, Paolo ; Oliva, Laura ; Cerruti, Fulvia ; Mariani, Elisabetta ; Pasqualetto, Elena ; Cenci, Simone ; Sitia, Roberto. / Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. In: European Journal of Immunology. 2008 ; Vol. 38, No. 3. pp. 658-667.
@article{8607fc1eee3a45018fe7c5b937988ad9,
title = "Dampening Ab responses using proteasome inhibitors following in vivo B cell activation",
abstract = "Upon encounter with Ag, B lymphocytes undergo terminal differentiation into plasma cells, highly specialized Ab secretors that mediate humoral immune responses. Profound changes adapt cellular morphology and proteome to the new secretory functions. Although a massive secretory activity is expected to require an efficient ubiquitin-proteasome degradation system, recent in vitro studies have surprisingly revealed that the proteasome function sharply decreases during plasma cell development, thereby limiting the proteolytic capacity. We challenged this paradigm in mouse models of B cell activation, and observed that following polyclonal activation, proteasome activity decreases more than previously reported in vitro. This decrease is linked to enhanced apoptosis after treatment with the potent anti-myeloma proteasome inhibitor PS-341. Accordingly, in vivo treatment with PS-341 decreases Ab titres in T-dependent and -independent mouse immunization models. This study provides the rationale for limiting the activity of Ab-secreting cells in vivo by impacting proteasome function.",
keywords = "Antibodies, Apoptosis, B cells, Cell differentiation, Proteasomes",
author = "Paolo Cascio and Laura Oliva and Fulvia Cerruti and Elisabetta Mariani and Elena Pasqualetto and Simone Cenci and Roberto Sitia",
year = "2008",
month = "3",
doi = "10.1002/eji.200737743",
language = "English",
volume = "38",
pages = "658--667",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "wiley",
number = "3",

}

TY - JOUR

T1 - Dampening Ab responses using proteasome inhibitors following in vivo B cell activation

AU - Cascio, Paolo

AU - Oliva, Laura

AU - Cerruti, Fulvia

AU - Mariani, Elisabetta

AU - Pasqualetto, Elena

AU - Cenci, Simone

AU - Sitia, Roberto

PY - 2008/3

Y1 - 2008/3

N2 - Upon encounter with Ag, B lymphocytes undergo terminal differentiation into plasma cells, highly specialized Ab secretors that mediate humoral immune responses. Profound changes adapt cellular morphology and proteome to the new secretory functions. Although a massive secretory activity is expected to require an efficient ubiquitin-proteasome degradation system, recent in vitro studies have surprisingly revealed that the proteasome function sharply decreases during plasma cell development, thereby limiting the proteolytic capacity. We challenged this paradigm in mouse models of B cell activation, and observed that following polyclonal activation, proteasome activity decreases more than previously reported in vitro. This decrease is linked to enhanced apoptosis after treatment with the potent anti-myeloma proteasome inhibitor PS-341. Accordingly, in vivo treatment with PS-341 decreases Ab titres in T-dependent and -independent mouse immunization models. This study provides the rationale for limiting the activity of Ab-secreting cells in vivo by impacting proteasome function.

AB - Upon encounter with Ag, B lymphocytes undergo terminal differentiation into plasma cells, highly specialized Ab secretors that mediate humoral immune responses. Profound changes adapt cellular morphology and proteome to the new secretory functions. Although a massive secretory activity is expected to require an efficient ubiquitin-proteasome degradation system, recent in vitro studies have surprisingly revealed that the proteasome function sharply decreases during plasma cell development, thereby limiting the proteolytic capacity. We challenged this paradigm in mouse models of B cell activation, and observed that following polyclonal activation, proteasome activity decreases more than previously reported in vitro. This decrease is linked to enhanced apoptosis after treatment with the potent anti-myeloma proteasome inhibitor PS-341. Accordingly, in vivo treatment with PS-341 decreases Ab titres in T-dependent and -independent mouse immunization models. This study provides the rationale for limiting the activity of Ab-secreting cells in vivo by impacting proteasome function.

KW - Antibodies

KW - Apoptosis

KW - B cells

KW - Cell differentiation

KW - Proteasomes

UR - http://www.scopus.com/inward/record.url?scp=43649096313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43649096313&partnerID=8YFLogxK

U2 - 10.1002/eji.200737743

DO - 10.1002/eji.200737743

M3 - Article

C2 - 18253932

AN - SCOPUS:43649096313

VL - 38

SP - 658

EP - 667

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 3

ER -